Literature DB >> 17537721

Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.

Sergey A Shiryaev1, Albert G Remacle, Boris I Ratnikov, Nicholas A Nelson, Alexei Y Savinov, Ge Wei, Massimo Bottini, Michele F Rega, Amelie Parent, Roxane Desjardins, Martin Fugere, Robert Day, Mojgan Sabet, Maurizio Pellecchia, Robert C Liddington, Jeffrey W Smith, Tomas Mustelin, Donald G Guiney, Michal Lebl, Alex Y Strongin.   

Abstract

Pathogens or their toxins, including influenza virus, Pseudomonas, and anthrax toxins, require processing by host proprotein convertases (PCs) to enter host cells and to cause disease. Conversely, inhibiting PCs is likely to protect host cells from multiple furin-dependent, but otherwise unrelated, pathogens. To determine if this concept is correct, we designed specific nanomolar inhibitors of PCs modeled from the extended cleavage motif TPQRERRRKKR downward arrowGL of the avian influenza H5N1 hemagglutinin. We then confirmed the efficacy of the inhibitory peptides in vitro against the fluorescent peptide, anthrax protective antigen (PA83), and influenza hemagglutinin substrates and also in mice in vivo against two unrelated toxins, anthrax and Pseudomonas exotoxin. Peptides with Phe/Tyr at P1' were more selective for furin. Peptides with P1' Thr were potent against multiple PCs. Our strategy of basing the peptide sequence on a furin cleavage motif known for an avian flu virus shows the power of starting inhibitor design with a known substrate. Our results confirm that inhibiting furin-like PCs protects the host from the distinct furin-dependent infections and lay a foundation for novel, host cell-focused therapies against acute diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537721     DOI: 10.1074/jbc.M703847200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

Review 2.  Processing of peptide and hormone precursors at the dibasic cleavage sites.

Authors:  Mohamed Rholam; Christine Fahy
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

3.  Substrate cleavage analysis of furin and related proprotein convertases. A comparative study.

Authors:  Albert G Remacle; Sergey A Shiryaev; Eok-Soo Oh; Piotr Cieplak; Anupama Srinivasan; Ge Wei; Robert C Liddington; Boris I Ratnikov; Amelie Parent; Roxane Desjardins; Robert Day; Jeffrey W Smith; Michal Lebl; Alex Y Strongin
Journal:  J Biol Chem       Date:  2008-05-27       Impact factor: 5.157

Review 4.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

5.  Specific and Selective Inhibitors of Proprotein Convertases Engineered by Transferring Serpin B8 Reactive-Site and Exosite Determinants of Reactivity to the Serpin α1PDX.

Authors:  Gonzalo Izaguirre; Marcelino Arciniega; Andrea G Quezada
Journal:  Biochemistry       Date:  2019-03-08       Impact factor: 3.162

6.  Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway.

Authors:  Meng Zhou; Youli Zhang; Hong Wei; Junbo He; Dawei Wang; Baoding Chen; Jian Zeng; Aihua Gong; Min Xu
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

7.  A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen.

Authors:  Katarzyna Gawlik; Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; Mingxing Ouyang; Yingxiao Wang; Alex Y Strongin
Journal:  PLoS One       Date:  2010-06-24       Impact factor: 3.240

8.  T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance.

Authors:  Marko Pesu; Wendy T Watford; Lai Wei; Lili Xu; Ivan Fuss; Warren Strober; John Andersson; Ethan M Shevach; Martha Quezado; Nicolas Bouladoux; Anton Roebroek; Yasmine Belkaid; John Creemers; John J O'Shea
Journal:  Nature       Date:  2008-09-11       Impact factor: 49.962

9.  Defensive strategies of Bacillus anthracis that promote a fatal disease.

Authors:  Jeremy Mogridge
Journal:  Drug Discov Today Dis Mech       Date:  2007

10.  A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C.

Authors:  Ajoy Basak; Abdel-Majid Khatib; Dayani Mohottalage; Sarmistha Basak; Maria Kolajova; Subhendu Sekhar Bag; Amit Basak
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.